In the past year Bio Nova has experienced very rapid growth in many existing markets. We have expanded into several new markets, and first shipments have gone to a number of countries where we are still waiting for the first implants. Clinical studies regarding Omniflow’s performance both in peripheral revascularisation and AV access have been initiated by independent investigators. Craig Newton has joined Bio Nova as Marketing Manager to facilitate further growth. EXISTING MARKETS Over the past year Bio Nova has seen significant growth in many of our existing markets in e.g. Australia, Brazil, Colombia, Germany, Italy, Spain and Switzerland. We would like to congratulate the distributors in these countries for an excellent job and we look forward to yet another successful year ahead. NEW MARKETS Bio Nova has recently experienced very rapid growth expanding into several new markets. New implants have been made in Belgium, Canada, Finland, Greece, Netherlands, Norway, Slovakia, and the United Kingdom. Initial shipments have also been sent to Denmark, India and Latvia where we are still waiting for first implants. Agreements have also been put in place with distribution partners in Egypt, Guatemala, Mexico and Sweden, and far-reaching discussions are being held with possible partners in Ireland, Portugal, Slovenia, South Africa and Thailand. CLINICAL STUDIES Two clinical phase IV studies covering Omniflow’s performance in comparison to other prosthesis materials have recently been initiated by independent investigator groups in Switzerland and the United Kingdom. One prospective randomised monocentre study comparing Omniflow with PTFE prostheses for arteriovenous access is already underway at the Royal London Hospital in the United Kingdom, lead by Mr Zafar Chawdhery. Another prospective randomised multicentre study comparing Omniflow with PTFE for below- knee bypass is being initiated at the Inselspital in Bern, Switzerland lead by Drs Jürg Schmidli and Hannu Savolainen. The protocol is currently being reviewed by the ethics committee and recruitment is expected to start late 2007 or early 2008.